2seventy Bio Sells Hemophilia A Candidate And MegaTAL In Vivo Gene Editing Technology To Novo Nordisk For Up To $40M
Portfolio Pulse from Benzinga Newsdesk
2seventy Bio has sold its Hemophilia A candidate and MegaTAL in vivo gene editing technology to Novo Nordisk for up to $40 million. This divestiture will allow 2seventy Bio to focus on the development and commercialization of Abecma.
June 26, 2024 | 8:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novo Nordisk has acquired 2seventy Bio's Hemophilia A candidate and MegaTAL gene editing technology for up to $40 million, expanding its portfolio in gene editing and hemophilia treatment.
The acquisition enhances Novo Nordisk's portfolio in gene editing and hemophilia treatment, potentially leading to future growth and innovation in these areas.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
2seventy Bio has divested its Hemophilia A candidate and MegaTAL gene editing technology to Novo Nordisk for up to $40 million. This move allows 2seventy Bio to concentrate on its core product, Abecma.
The divestiture provides 2seventy Bio with significant capital and allows the company to focus on its core product, Abecma, which could lead to better financial performance and investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100